Developer docs
API playgroundTry for free, no card

Search company profiles

Shoreline Biosciences

Full company profile

uuid0000dxu

Namestring
Shoreline Biosciences
Legal namestring
Shoreline Biosciences
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Shoreline Biosciences is a clinical-stage biotechnology company developing immunotherapies derived from induced pluripotent stem cells (iPSCs), with the stated goal of producing allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, in contrast to patient-specific autologous CAR-T approaches. The company's core technology is its iPSC platform, which is applied to generate cell-based immunotherapies targeting cancer and other serious diseases. The pipeline and platform are positioned to address limitations of current autologous cell therapies, including long manufacturing turnaround times, patient-specific processing constraints, and scalability bottlenecks.

The business model is partnership- and licensing-driven rather than direct commercialization. Shoreline raises venture capital and enters into strategic co-development agreements with established pharmaceutical companies to advance its candidates through development and toward commercialization. Its two named anchor partners are Kite Pharmaceuticals (a Gilead Sciences company specializing in CAR-T cell therapies) and BeiGene (a global biopharmaceutical company with broad oncology and immunology capabilities), both announced in November 2021. Revenue, when and if it materializes, would come in the form of milestone payments and royalties under these licensing/co-development arrangements; the company has no approved products and no disclosed pricing model. Headcount sits in the 51-100 range, consistent with an early-clinical biotech scaling manufacturing capabilities alongside pipeline growth.

Shoreline is headquartered in La Jolla, California (United States), was founded in 2020, and has raised approximately $186 million across three disclosed funding rounds between July 2020 and November 2021, with the largest $140 million round led by Ally Bridge Group and supported by a 15-investor syndicate including both pharma partners (Kite Pharma, BeiGene). The data available in source materials ends in late 2021 and does not reflect any subsequent clinical milestones, additional financings, or pipeline updates.

Short descriptiontext

Shoreline Biosciences is a La Jolla-based clinical-stage biotechnology company developing allogeneic iPSC-derived cell immunotherapies for cancer and other serious diseases, advancing its pipeline through strategic co-development partnerships with Kite Pharmaceuticals and BeiGene.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cell immunotherapy development, iPSC-based therapies, allogeneic cell therapy, oncology cell therapy, regenerative medicine platform
Industry2 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Immunotherapy Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1iPSC-based Immunotherapy Development and Licensing
TypeLicensing Royalties
Description

As a pre-commercial biotechnology company, Shoreline Biosciences generates value through partnership agreements with pharmaceutical companies for the co-development of cell therapies, potentially receiving milestone payments and royalties upon successful commercialization of partnered therapies.

biospace.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Shoreline Biosciences develops immunotherapies derived from induced pluripotent stem cells (iPSCs) intended to treat seriously ill patients, particularly cancer. The company focuses on allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, addressing limitations of autologous CAR-T approaches. Pipeline development is conducted through strategic co-development partnerships with pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Shoreline Biosciences is a biotechnology company developing iPSC-based cell immunotherapies. The company operates a pipeline-focused approach with its core iPSC-derived immunotherapies platform, supported by strategic partnerships with Kite Pharmaceuticals and BeiGene for developing cell therapies targeting various diseases. The company's product portfolio centers on allogeneic cell therapies manufactured from iPSCs, with the financing supporting pipeline growth and manufacturing capabilities expansion.

Product and service1 record
1iPSC-based Immunotherapies
CategoryCell Immunotherapy
Description

Cell immunotherapies derived from induced pluripotent stem cells (iPSCs) targeting various diseases including cancer; designed to enable allogeneic, off-the-shelf cell therapy manufacturing at scale. Developed for pharmaceutical partners such as Kite Pharmaceuticals and BeiGene.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-02
Description

Shoreline Biosciences entered into a strategic partnership with Kite Pharmaceuticals to develop cell therapies targeting various diseases. Kite Pharma is a Gilead Sciences company specializing in CAR-T cell therapies, bringing expertise in cell therapy manufacturing and commercialization to the partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-02
Description

Shoreline Biosciences partnered with BeiGene, a global biopharmaceutical company, to develop cell therapies targeting various diseases. The partnership leverages BeiGene's global development and commercialization capabilities in oncology and immunology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Precision BioSciences develops allogeneic CAR-T cell therapies using ARCUS gene editing. Direct cell therapy peer targeting oncology with off-the-shelf, scalable manufacturing.

TypeDirect peer
Description

Century Therapeutics develops iPSC-derived allogeneic cell therapies (NK and T cells) with engineered resistance to the tumor microenvironment. Closely overlapping platform technology and indication focus with Shoreline.

TypeEmerging player
Description

Editas Medicine develops CRISPR-based gene-edited cell therapies, including allogeneic NK and T-cell approaches. Comparable as a gene-editing cell therapy peer with overlapping technology platforms.

TypeBroad incumbent
Description

Cellectis is a clinical-stage gene-editing company developing allogeneic CAR-T (UCART) therapies and TALEN-edited cell products. Comparable as a broader allogeneic cell therapy player with established manufacturing platforms.

TypeDirect peer
Description

Allogene is a pioneer in allogeneic CAR-T cell therapy, using healthy donor cells (rather than iPSC) for off-the-shelf products. Direct allogeneic cell therapy peer and leading competitor in the same commercial category Shoreline targets.

TypeDirect peer
Description

Adicet Bio develops off-the-shelf allogeneic gamma-delta T-cell therapies for cancer and autoimmune disease. Directly comparable to Shoreline in targeting allogeneic, scalable cell therapy manufacturing.

TypeDirect peer
Description

Fate Therapeutics is the leading clinical-stage developer of iPSC-derived NK and T-cell immunotherapies — directly comparable to Shoreline's core iPSC allogeneic platform. Both companies pursue off-the-shelf, multiplexed engineered cell therapies for oncology.

TypeDirect peer
Description

Nkarta develops engineered NK cell therapies for cancer, including allogeneic, off-the-shelf approaches. Comparable as a cell therapy peer targeting hematologic and solid tumors with a partner-validated platform.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading gene-editing biotech with allogeneic cell therapy programs (including CAR-T) and a Vertex partnership. Comparable as a broad incumbent in gene-edited cell therapy.

TypeDirect peer
Description

Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable peer in the allogeneic cell therapy category with a similar partner-driven business model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Shoreline Biosciences

Cell Immunotherapy Developmentshorelinebio.com

Shoreline Biosciences is a La Jolla-based clinical-stage biotechnology company developing allogeneic iPSC-derived cell immunotherapies for cancer and other serious diseases, advancing its pipeline through strategic co-development partnerships with Kite Pharmaceuticals and BeiGene.

What Shoreline Biosciences does

Shoreline Biosciences is a clinical-stage biotechnology company developing immunotherapies derived from induced pluripotent stem cells (iPSCs), with the stated goal of producing allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, in contrast to patient-specific autologous CAR-T approaches. The company's core technology is its iPSC platform, which is applied to generate cell-based immunotherapies targeting cancer and other serious diseases. The pipeline and platform are positioned to address limitations of current autologous cell therapies, including long manufacturing turnaround times, patient-specific processing constraints, and scalability bottlenecks.

The business model is partnership- and licensing-driven rather than direct commercialization. Shoreline raises venture capital and enters into strategic co-development agreements with established pharmaceutical companies to advance its candidates through development and toward commercialization. Its two named anchor partners are Kite Pharmaceuticals (a Gilead Sciences company specializing in CAR-T cell therapies) and BeiGene (a global biopharmaceutical company with broad oncology and immunology capabilities), both announced in November 2021. Revenue, when and if it materializes, would come in the form of milestone payments and royalties under these licensing/co-development arrangements; the company has no approved products and no disclosed pricing model. Headcount sits in the 51-100 range, consistent with an early-clinical biotech scaling manufacturing capabilities alongside pipeline growth.

Shoreline is headquartered in La Jolla, California (United States), was founded in 2020, and has raised approximately $186 million across three disclosed funding rounds between July 2020 and November 2021, with the largest $140 million round led by Ally Bridge Group and supported by a 15-investor syndicate including both pharma partners (Kite Pharma, BeiGene). The data available in source materials ends in late 2021 and does not reflect any subsequent clinical milestones, additional financings, or pipeline updates.

Shoreline Biosciences firmographics

Firmographics
Name
Shoreline Biosciences
Legal name
Shoreline Biosciences
Website
https://shorelinebio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Shoreline Biosciences is a La Jolla-based clinical-stage biotechnology company developing allogeneic iPSC-derived cell immunotherapies for cancer and other serious diseases, advancing its pipeline through strategic co-development partnerships with Kite Pharmaceuticals and BeiGene.
Ownership category
akta.pro rank

Shoreline Biosciences industry classification

Industry
Product category
Cell Immunotherapy Development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell immunotherapy development
  • IPSC-based therapies
  • Allogeneic cell therapy
  • Oncology cell therapy
  • Regenerative medicine platform

Where Shoreline Biosciences is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Markets served

Shoreline Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. iPSC-based Immunotherapy Development and Licensing: As a pre-commercial biotechnology company, Shoreline Biosciences generates value through partnership agreements with pharmaceutical companies for the co-development of cell therapies, potentially receiving milestone payments and royalties upon successful commercialization of partnered therapies.

Go-to-market motion1 record

Distribution channels1 record

Shoreline Biosciences product offering

Product offering

Core offering

Shoreline Biosciences develops immunotherapies derived from induced pluripotent stem cells (iPSCs) intended to treat seriously ill patients, particularly cancer. The company focuses on allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, addressing limitations of autologous CAR-T approaches. Pipeline development is conducted through strategic co-development partnerships with pharmaceutical companies.

Product overview

Shoreline Biosciences is a biotechnology company developing iPSC-based cell immunotherapies. The company operates a pipeline-focused approach with its core iPSC-derived immunotherapies platform, supported by strategic partnerships with Kite Pharmaceuticals and BeiGene for developing cell therapies targeting various diseases. The company's product portfolio centers on allogeneic cell therapies manufactured from iPSCs, with the financing supporting pipeline growth and manufacturing capabilities expansion.

Differentiator

Problem solved

Functional benefit

Products and services

  • iPSC-based Immunotherapies Cell immunotherapies derived from induced pluripotent stem cells (iPSCs) targeting various diseases including cancer; designed to enable allogeneic, off-the-shelf cell therapy manufacturing at scale. Developed for pharmaceutical partners such as Kite Pharmaceuticals and BeiGene.

Companies that use Shoreline Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Shoreline Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Shoreline Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Kite PharmaceuticalscoreStrategic or Co-development Partner · 2 November 2021Shoreline Biosciences entered into a strategic partnership with Kite Pharmaceuticals to develop cell therapies targeting various diseases. Kite Pharma is a Gilead Sciences company specializing in CAR-T cell therapies, bringing expertise in cell therapy manufacturing and commercialization to the partnership.
  • BeiGenecoreStrategic or Co-development Partner · 2 November 2021Shoreline Biosciences partnered with BeiGene, a global biopharmaceutical company, to develop cell therapies targeting various diseases. The partnership leverages BeiGene's global development and commercialization capabilities in oncology and immunology.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Shoreline Biosciences competitors and assessment

Company assessment

Direct peers

  • Precision BioSciences: Precision BioSciences develops allogeneic CAR-T cell therapies using ARCUS gene editing. Direct cell therapy peer targeting oncology with off-the-shelf, scalable manufacturing.
  • Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies (NK and T cells) with engineered resistance to the tumor microenvironment. Closely overlapping platform technology and indication focus with Shoreline.
  • Allogene Therapeutics: Allogene is a pioneer in allogeneic CAR-T cell therapy, using healthy donor cells (rather than iPSC) for off-the-shelf products. Direct allogeneic cell therapy peer and leading competitor in the same commercial category Shoreline targets.
  • Adicet Bio: Adicet Bio develops off-the-shelf allogeneic gamma-delta T-cell therapies for cancer and autoimmune disease. Directly comparable to Shoreline in targeting allogeneic, scalable cell therapy manufacturing.
  • Fate Therapeutics: Fate Therapeutics is the leading clinical-stage developer of iPSC-derived NK and T-cell immunotherapies — directly comparable to Shoreline's core iPSC allogeneic platform. Both companies pursue off-the-shelf, multiplexed engineered cell therapies for oncology.
  • Nkarta Therapeutics: Nkarta develops engineered NK cell therapies for cancer, including allogeneic, off-the-shelf approaches. Comparable as a cell therapy peer targeting hematologic and solid tumors with a partner-validated platform.
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable peer in the allogeneic cell therapy category with a similar partner-driven business model.

Emerging players

  • Editas Medicine: Editas Medicine develops CRISPR-based gene-edited cell therapies, including allogeneic NK and T-cell approaches. Comparable as a gene-editing cell therapy peer with overlapping technology platforms.

Broad incumbents

  • Cellectis: Cellectis is a clinical-stage gene-editing company developing allogeneic CAR-T (UCART) therapies and TALEN-edited cell products. Comparable as a broader allogeneic cell therapy player with established manufacturing platforms.
  • CRISPR Therapeutics: CRISPR Therapeutics is a leading gene-editing biotech with allogeneic cell therapy programs (including CAR-T) and a Vertex partnership. Comparable as a broad incumbent in gene-edited cell therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Shoreline Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Shoreline Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Shoreline Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Shoreline Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shoreline Biosciences

What does Shoreline Biosciences do?

Shoreline Biosciences develops immunotherapies derived from induced pluripotent stem cells (iPSCs) intended to treat seriously ill patients, particularly cancer. The company focuses on allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, addressing limitations of autologous CAR-T approaches. Pipeline development is conducted through strategic co-development partnerships with pharmaceutical companies.

Is Shoreline Biosciences a public or private company?

Shoreline Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Shoreline Biosciences founded?

Shoreline Biosciences was founded in 2020. It employs 1 to 10 people.

Where is Shoreline Biosciences based?

Shoreline Biosciences is headquartered in La Jolla, United States, in the North America region.

How does Shoreline Biosciences make money?

One revenue line is on record: iPSC-based Immunotherapy Development and Licensing.

Who are Shoreline Biosciences's main competitors?

Direct peers on record are Precision BioSciences, Century Therapeutics, Allogene Therapeutics, Adicet Bio, Fate Therapeutics, Nkarta Therapeutics and Caribou Biosciences. Editas Medicine is listed as an emerging player. Broad incumbents are Cellectis and CRISPR Therapeutics.

Does Shoreline Biosciences have an API?

No public API is recorded for Shoreline Biosciences.

What industry is Shoreline Biosciences in?

Shoreline Biosciences's product category is Cell Immunotherapy Development. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSHORELINE BIOSCIENCES WINS A COMPREHENSIVE SUMMARY JUDGEMENT VICTORY ON ALL CLAIMS BROUGHT BY FATE THERAPEUTICS AND WHITEHEAD INSTITUTE ON IPSC GENERATION AND USEShoreline Biosciences won a summary judgement victory in its patent litigation with Fate Therapeutics and the Whitehead Institute in the U.S. District Court for the Southern District of California on September 7, 2023. The court ruled that the Fate/Whitehead patents related to Somatic Cell Nuclear Transfer (SCNT) did not cover Shoreline's use of induced pluripotent stem cells (iPSCs) in its drug development programs, granting non-infringement on all claims. The company's CEO called it a complete victory against what he described as a meritless lawsuit that wasted capital and resources.GlobeNewswireEditas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business UpdatesEditas Medicine reported Q4 2022 net loss of $60.7 million and full-year 2022 net loss of $220.4 million. The company remains on track to dose 20 SCD patients by year-end and dose the first TDT patient in Q1 2023, with a clinical update for RUBY by mid-2023. It also entered a definitive agreement to sell its iNK cell franchise to Shoreline Biosciences.PR NewswireShoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical OfficerShoreline Biosciences, a San Diego-based biopharmaceutical company developing iPSC-derived cellular immunotherapies, announced the appointment of Mauro P. Avanzi, M.D., Ph.D. as Chief Medical Officer. Dr. Avanzi brings over fifteen years of clinical experience in cellular therapies, including prior roles at Neogene Therapeutics and Kite Pharma where he supported multiple clinical programs and contributed to the commercial approval of Yescarta for indolent NHL. The company stated this appointment will strengthen its capabilities as it advances its pipeline of iNK and iMAC cell therapy programs toward clinical development.BioSpaceEditas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing TechnologiesEditas Medicine and Shoreline Biosciences entered a definitive agreement for Shoreline to acquire Editas' iNK cell franchise and related manufacturing technologies. Shoreline will also obtain exclusive licenses to SLEEK knock-in technology and AsCas12a, with upfront and milestone payments. The deal is part of Editas' strategic reprioritization toward in vivo gene editing.PR NewswireSHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION ON NOVEL MANUFACTURING METHOD OF INK CELLS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2022 MEETINGShoreline Biosciences announced it will present new data on its iNK platform at the American Society of Hematology 2022 annual meeting in New Orleans from December 10-13, 2022. The oral presentation will showcase a novel manufacturing process for clinical-scale cGMP production of CISH knock-out induced pluripotent stem cell-derived natural killer (iNK) cells. A companion poster will cover next-generation CAR designs for iPSC-derived NK cell therapies targeting both solid and liquid tumors.PR NewswireSHORELINE BIOSCIENCES ANNOUNCES APPOINTMENT OF CELL THERAPY MANUFACTURING VETERAN CHARLES CALDERARO III AS CHIEF TECHNICAL OFFICERShoreline Biosciences, a San Diego-based biopharmaceutical company developing iPSC-derived cellular immunotherapies, announced the appointment of Charles Calderaro III as Chief Technical Officer. Calderaro brings 30 years of manufacturing and engineering experience, most recently serving as Global Head of Technical Operations at Kite, a Gilead company, where he oversaw commercial-scale CAR-T cell therapy manufacturing. The company stated the hire is intended to support its planned scalable manufacturing system for iNK and iMAC cell therapy platforms.PR NewswireSHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION on ipsc-derived NK cell (iNK) platform AT INNATE KILLER SUMMIT meeting 2022Shoreline Biosciences announced that its Co-Founder and Chief Medical Officer William Sandborn will deliver an oral presentation titled "Extending the Proliferative Capacity & Persistence of NK Cells In Vivo" at the Innate Killer Summit 2022 meeting in San Diego on March 31, 2022. The presentation will take place during the Discovery session focused on overcoming exhaustion and maximizing persistence of natural killer cells. The company is developing next-generation cellular immunotherapies using its proprietary iPSC-derived NK cell and macrophage platforms, with strategic partnerships with Kite (a Gilead company) and BeiGene.FierceBiotechPfizer cancer vaccine science chief poached by Gilead-backed Shoreline BiosciencesShoreline Biosciences hired Robert Hollingsworth, Pfizer's cancer vaccines chief, as its chief scientific officer. He will lead the company's natural killer cell therapy pipeline, which has attracted Gilead's Kite Pharma interest in a potential deal exceeding $2.3 billion. Shoreline also received $140 million in financing from Gilead, BeiGene, and VCs.BioSpaceShoreline Biosciences Appoints Robert Hollingsworth, Ph.D., As Chief Scientific OfficerShoreline Biosciences appointed Robert Hollingsworth, Ph.D., as Chief Scientific Officer. He previously served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics at Pfizer, where he advanced five programs into clinical development. He will lead innovation across Shoreline's iNK and iMACs platforms.PR NewswireShoreline Biosciences to Present Multiple Posters on iPSC-Derived NK Cell Platform at AACR Annual Meeting 2022Shoreline Biosciences announced that two of its abstracts have been accepted for poster presentations at the American Association for Cancer Research annual meeting in New Orleans from April 8-13, 2022. The presentations will showcase the company's iPSC-derived natural killer cell platform and screening methodology for developing next-generation CAR-NK cell immunotherapies. This marks Shoreline's first time presenting at a major scientific conference as the company advances its cellular immunotherapy pipeline toward clinical development.